Apyx Medical Corporation (APYX)
| Market Cap | 155.40M |
| Revenue (ttm) | 52.84M |
| Net Income (ttm) | -11.21M |
| Shares Out | 41.83M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,488 |
| Open | 3.740 |
| Previous Close | 3.760 |
| Day's Range | 3.600 - 3.800 |
| 52-Week Range | 0.849 - 4.500 |
| Beta | 1.54 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+74.97%) |
| Earnings Date | May 7, 2026 |
About APYX
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparo... [Read more]
Financial Performance
In 2025, Apyx Medical's revenue was $52.84 million, an increase of 9.86% compared to the previous year's $48.10 million. Losses were -$11.21 million, -52.22% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for APYX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 74.97% from the latest price.
News
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the ...
Renuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla.
Apyx Medical Transcript: The Citizens Life Sciences Conference 2026
AYON, a fully integrated surgical aesthetics system, is driving strong growth and market interest by consolidating multiple technologies and addressing new demand from GLP-1-induced skin laxity. The company is achieving operational efficiencies, expanding internationally, and expects 17%-19% revenue growth this year.
Apyx Medical Earnings Call Transcript: Q4 2025
Record Q4 revenue and strong AYON system adoption drove 35% year-over-year growth, with positive EBITDA and improved cash flow. 2026 guidance projects continued double-digit growth in surgical aesthetics, with plans for international expansion and further product enhancements.
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...
Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference
CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the A...
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AY...
Apyx Medical Earnings Call Transcript: Q3 2025
Revenue grew 12% year-over-year to $12.9M, driven by the AYON launch and strong Surgical Aesthetics sales. Gross margin improved to 64.4%, and net loss narrowed significantly. Updated 2025 guidance reflects higher expectations for AYON, with cash expected to last through 2027.
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technolo...
Apyx Medical Transcript: Status Update
GLP-1-driven demand is fueling growth in surgical aesthetics, with AON’s integrated platform delivering superior clinical outcomes, efficiency, and patient satisfaction. Surgeons report increased procedure volumes and strong interest in the upcoming power-assisted handpiece.
Apyx Medical Transcript: Canaccord Genuity’s 45th Annual Growth Conference
GLP-1 therapies are reshaping the aesthetics market, driving demand for skin tightening and surgical interventions. New product launches like AYON and strong Renuvion sales support raised financial guidance and global expansion, with a focus on surgeon partnerships and operational efficiency.
Apyx Medical Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 6% year-over-year, but gross margin improved and net loss narrowed due to cost reductions. Strong demand for AYON and Renuvion, especially in new markets like China, led to raised 2025 revenue guidance. Cash position remains solid.
Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform ...
Apyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference
CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technolog...
Renuvion® Brings Real Transformations to the Runway at Miami Swim Week
Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla. , May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) (...
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion l...
Apyx Medical Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined 8% year-over-year to $9.4M, but advanced energy sales grew 6% and gross margin improved to 60.1%. Cost controls reduced net loss and cash burn, and 2025 guidance was reaffirmed with the AYON launch expected in H2 pending FDA clearance.
Renuvion Introduces Television Star Dolores Catania as Chief of Confidence
Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- ...
Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures
Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due ...
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technol...
Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/...
Apyx Medical Earnings Call Transcript: Q4 2024
Q4 2024 revenue declined 3% year-over-year, but advanced energy sales grew 30% sequentially from Q3. Cost reductions and a direct offering improved the financial position, while 2025 guidance projects stable revenue and margins. Aion system launch is expected in H2 2025, pending FDA clearance.